Does the media prefer KYMR or TARS?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.62 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SYRE or TARS?

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.76 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRNX or TARS?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.71 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer QGEN or TARS?

In the previous week, Qiagen had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 10 mentions for Qiagen and 8 mentions for Tarsus Pharmaceuticals. Qiagen's average media sentiment score of 0.89 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Tarsus Pharmaceuticals (TARS) Competitors

$59.85 +2.16 (+3.74%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$59.92 +0.07 (+0.13%)

As of 07/17/2026 05:14 PM Eastern

Compare

TARS vs. KYMR, SYRE, PRAX, CRNX, and QGEN

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? MarketBeat compares Tarsus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tarsus Pharmaceuticals include Kymera Therapeutics (KYMR), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), Crinetics Pharmaceuticals (CRNX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Tarsus Pharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.62 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	242.88	-$311.35M	-$3.57	N/A
Tarsus Pharmaceuticals	$451.36M	5.70	-$66.42M	-$1.14	N/A

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Kymera Therapeutics' net margin of -611.94%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Kymera Therapeutics currently has a consensus target price of $122.64, suggesting a potential upside of 5.93%. Tarsus Pharmaceuticals has a consensus target price of $90.67, suggesting a potential upside of 51.49%. Given Tarsus Pharmaceuticals' higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Tarsus Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,903.62	-$155.20M	-$2.08	N/A
Tarsus Pharmaceuticals	$451.36M	5.70	-$66.42M	-$1.14	N/A

Spyre Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.76 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics presently has a consensus target price of $101.42, indicating a potential upside of 1.18%. Tarsus Pharmaceuticals has a consensus target price of $90.67, indicating a potential upside of 51.49%. Given Tarsus Pharmaceuticals' higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Tarsus Pharmaceuticals beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Praxis Precision Medicines has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Tarsus Pharmaceuticals presently has a consensus price target of $90.67, suggesting a potential upside of 51.49%. Praxis Precision Medicines has a consensus price target of $563.50, suggesting a potential upside of 79.22%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

Tarsus Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	5.70	-$66.42M	-$1.14	N/A
Praxis Precision Medicines	$8.55M	1,025.23	-$303.27M	-$13.37	N/A

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.91 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Praxis Precision Medicines beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.71 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crinetics Pharmaceuticals presently has a consensus price target of $78.27, suggesting a potential downside of 6.66%. Tarsus Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 51.49%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Tarsus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,148.34	-$465.32M	-$5.13	N/A
Tarsus Pharmaceuticals	$451.36M	5.70	-$66.42M	-$1.14	N/A

Summary

Tarsus Pharmaceuticals beats Crinetics Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Qiagen had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 10 mentions for Qiagen and 8 mentions for Tarsus Pharmaceuticals. Qiagen's average media sentiment score of 0.89 beat Tarsus Pharmaceuticals' score of 0.25 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Qiagen has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.06	$424.88M	$1.91	21.56
Tarsus Pharmaceuticals	$451.36M	5.70	-$66.42M	-$1.14	N/A

Qiagen has a net margin of 19.16% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Qiagen's return on equity of 14.40% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Qiagen presently has a consensus target price of $43.34, suggesting a potential upside of 5.23%. Tarsus Pharmaceuticals has a consensus target price of $90.67, suggesting a potential upside of 51.49%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

70.0% of Qiagen shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Qiagen beats Tarsus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.48B	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-52.50	20.85	27.14	23.89
Price / Sales	5.70	304.43	524.02	90.49
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	7.40	8.26	10.69	6.18
Net Income	-$66.42M	$23.83M	$3.59B	$331.73M
7 Day Performance	2.94%	-3.48%	-2.18%	-2.04%
1 Month Performance	-5.24%	2.58%	1.63%	-2.14%
1 Year Performance	38.38%	45.93%	25.56%	17.28%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	2.7747 of 5 stars	$59.85 +3.7%	$90.67 +51.5%	+44.6%	$2.48B	$451.36M	N/A	50
KYMR Kymera Therapeutics	1.5361 of 5 stars	$113.07 +2.4%	$121.73 +7.7%	+149.8%	$9.33B	$39.21M	N/A	170	Analyst Forecast
SYRE Spyre Therapeutics	1.4836 of 5 stars	$104.56 +11.6%	$101.42 -3.0%	+493.4%	$9.21B	$890K	N/A	73
PRAX Praxis Precision Medicines	3.3081 of 5 stars	$321.10 +2.1%	$563.50 +75.5%	+472.3%	$8.95B	$8.55M	N/A	110	Gap Down
CRNX Crinetics Pharmaceuticals	1.3816 of 5 stars	$83.72 +0.1%	$78.27 -6.5%	+154.0%	$8.83B	$7.70M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. KYMR, SYRE, PRAX, CRNX, and QGEN

How does Tarsus Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Tarsus Pharmaceuticals compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. KYMR, SYRE, PRAX, CRNX, and QGEN

How does Tarsus Pharmaceuticals compare to Kymera Therapeutics?

Does the media prefer KYMR or TARS?

Which has more risk and volatility, KYMR or TARS?

Which has preferable valuation and earnings, KYMR or TARS?

Is KYMR or TARS more profitable?

Do analysts recommend KYMR or TARS?

Do institutionals and insiders have more ownership in KYMR or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Spyre Therapeutics?

Which has preferable earnings and valuation, SYRE or TARS?

Which has more volatility & risk, SYRE or TARS?

Is SYRE or TARS more profitable?

Do institutionals & insiders believe in SYRE or TARS?

Does the media refer more to SYRE or TARS?

Do analysts rate SYRE or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Is TARS or PRAX more profitable?

Do analysts recommend TARS or PRAX?

Which has better valuation & earnings, TARS or PRAX?

Does the media prefer TARS or PRAX?

Which has more volatility & risk, TARS or PRAX?

Do insiders & institutionals have more ownership in TARS or PRAX?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Does the media refer more to CRNX or TARS?

Do analysts recommend CRNX or TARS?

Do institutionals and insiders have more ownership in CRNX or TARS?

Which has more risk and volatility, CRNX or TARS?

Is CRNX or TARS more profitable?

Which has stronger valuation and earnings, CRNX or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Qiagen?

Does the media prefer QGEN or TARS?

Which has more volatility & risk, QGEN or TARS?

Which has higher earnings and valuation, QGEN or TARS?

Is QGEN or TARS more profitable?

Do analysts rate QGEN or TARS?

Do institutionals & insiders hold more shares of QGEN or TARS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools